Dechra Pharmaceuticals PLC

LSE:DPH Stok Raporu

Piyasa değeri: UK£4.4b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Dechra Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 4/4

Dechra Pharmaceuticals' CEO'su Ian Page, Nov2001 tarihinde atandı, in görev süresi 22.17 yıldır. in toplam yıllık tazminatı £ 1.04M olup, şirket hissesi ve opsiyonları dahil olmak üzere 59.9% maaş ve 40.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.36% ine doğrudan sahiptir ve bu hisseler £ 15.64M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.8 yıl ve 4.3 yıldır.

Anahtar bilgiler

Ian Page

İcra Kurulu Başkanı

UK£1.0m

Toplam tazminat

CEO maaş yüzdesi59.9%
CEO görev süresi22.2yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi4.8yrs
Yönetim Kurulu ortalama görev süresi4.3yrs

Son yönetim güncellemeleri

Recent updates

Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt

May 31
Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt

A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Mar 28
A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt

Mar 02
We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt

Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125

Mar 02
Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Dec 09
Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289

Oct 06
Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289

Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year

Sep 22
Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289

Sep 08
Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Aug 18
Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

Aug 02
Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Jun 10
These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

May 08
Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?

Apr 22
Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

Feb 23
Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 29
Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value

Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?

Jan 11
Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Dec 04
Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

Oct 15
It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

Sep 25
Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29

Sep 11
Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29

With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting

Sep 08
With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting

Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?

Jun 17
Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?

Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?

Apr 09
Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?

Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet

Mar 05
Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet

Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 17
Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Feb 02
Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

CEO Tazminat Analizi

Ian Page'un ücretlendirmesi Dechra Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2023UK£1mUK£621k

-UK£28m

Mar 31 2023n/an/a

UK£6m

Dec 31 2022n/an/a

UK£40m

Sep 30 2022n/an/a

UK£49m

Jun 30 2022UK£2mUK£597k

UK£58m

Mar 31 2022n/an/a

UK£66m

Dec 31 2021n/an/a

UK£73m

Sep 30 2021n/an/a

UK£64m

Jun 30 2021UK£3mUK£551k

UK£56m

Mar 31 2021n/an/a

UK£50m

Dec 31 2020n/an/a

UK£44m

Sep 30 2020n/an/a

UK£39m

Jun 30 2020UK£2mUK£517k

UK£34m

Mar 31 2020n/an/a

UK£31m

Dec 31 2019n/an/a

UK£29m

Sep 30 2019n/an/a

UK£30m

Jun 30 2019UK£3mUK£500k

UK£31m

Mar 31 2019n/an/a

UK£28m

Dec 31 2018n/an/a

UK£25m

Sep 30 2018n/an/a

UK£30m

Jun 30 2018UK£3mUK£500k

UK£36m

Mar 31 2018n/an/a

UK£40m

Dec 31 2017n/an/a

UK£43m

Sep 30 2017n/an/a

UK£35m

Jun 30 2017UK£3mUK£490k

UK£26m

Tazminat ve Piyasa: Ian 'nin toplam tazminatı ($USD 1.31M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 3.65M ).

Tazminat ve Kazançlar: Ian 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Ian Page (62 yo)

22.2yrs

Görev süresi

UK£1,037,000

Tazminat

Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Ian Page
CEO, MD & Executive Director22.2yrsUK£1.04m0.36%
£ 15.6m
Paul Sandland
CFO & Executive Director4.8yrsUK£641.00k0.010%
£ 452.7k
Patrick Meeus
Chief Scientific Officer1.5yrsVeri yokVeri yok
Jamie Adams
Chief Information Officer1.6yrsVeri yokVeri yok
Katy Clough
Chief People Officerno dataVeri yokVeri yok
Mike Eldred
President of North Americano dataVeri yokVeri yok
Melanie Hall
Company Secretary6.5yrsVeri yokVeri yok

4.8yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: DPH 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Ian Page
CEO, MD & Executive Director26.6yrsUK£1.04m0.36%
£ 15.6m
Paul Sandland
CFO & Executive Director4.3yrsUK£641.00k0.010%
£ 452.7k
Geeta Gopalan
Independent Non-Executive Directorless than a yearUK£36.00kVeri yok
Lawson MacArtney
Senior Independent Director7.1yrsUK£107.00k0.0052%
£ 227.2k
Alison Platt
Independent Non-Executive Chairman3.8yrsUK£207.00k0.0033%
£ 143.6k
Lisa Morrison
Designated Non-Executive Director4.9yrsUK£72.00k0.0012%
£ 53.3k
John Shipsey
Independent Non-Executive Director1.6yrsUK£73.00k0.00053%
£ 23.3k

4.3yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DPH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).